Leicester’s Glenfield Hospital is to introduce the latest stroke-preventing cardiac implant, through Althea’s Consumable Management Service (CMS). Background Atrial fibrillation … continue reading “Glenfield to become one of first UK Hospitals to offer Boston Scientific’s WATCHMAN FLX™”
Boston Scientific Corporation has announced the CE Mark approval of its Vercise™ Neural Navigator 3 directional Deep Brain Stimulation (DBS) programming … continue reading “CE Mark for Boston Scientific’s VERCISE™ Neural Navigator 3 Programming Software”
This new implant provides patients with a durable, natural-feeling implant for the treatment of erectile dysfunction. Background Erectile dysfunction (ED) … continue reading “Boston Scientific’s New TACTRA™ Penile Prosthesis”
Company says acquisition demonstrates continued commitment to structural heart portfolio
Approval grants MR-conditional labeling to all EMBLEM S-ICD Systems, further expanding the company’s ImageReady™ portfolio
Full-Body MRI access expands Spinal Cord Stimulation offering and brings customized therapy to more patients suffering from chronic pain
Ureteroscopes are used 4600 times a day to examine the urinary tract. Boston Scientific is claiming a first with its new disposable offering, which does sound like a game changer
ZelanteDVT catheter is the first AngioJet catheter designed specifically to treat DVT
Boston Scientific Corporation is to acquire Xlumena, Inc., developer of Endoscopic Ultrasound-guided transluminal drainage devices
Boston Scientific will be hoping its new S-ICD will prove popular based on its advantages over conventionally placed leads
First-Of-Its-Kind alternative to long-term Warfarin therapy for stroke risk reduction in patients with non-valvular atrial fibrillation
The new Extended Longevity ICDs, featuring EnduraLife battery technology promise almost twelve years
Whatever the value of retrospective data, Boston Scientific is touting results that make a solid case for its Precision Spectra spinal cord stimulator system
Boston Scientific reports that its SYNERGY™ Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium Coronary Stent System met its primary endpoint in the first successful U.S. pivotal trial of a bioabsorbable polymer stent.
When implanted with Boston Scientific’s INGEVITY™ leads, Boston Scientific’s ACCOLADE pacemakers are the first to enable patients to receive full-body MRI scans in both 1.5 Tesla and 3.0 Tesla systems.
Expert Panel review has culminateded in a vote in favour of Boston Scientific Corporation’s WATCHMAN™ Left Atrial Appendage Closure Device.